z-logo
Premium
Demonstration of functional M 3 ‐muscarinic receptors in ventricular cardiomyocytes of adult rats
Author(s) -
Pönicke Klaus,
HeinrothHoffmann Ingrid,
Brodde OttoErich
Publication year - 2003
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0704997
Subject(s) - carbachol , pirenzepine , muscarinic acetylcholine receptor , endocrinology , medicine , receptor , pertussis toxin , receptor antagonist , inositol phosphate , antagonist , chemistry , phospholipase c , muscarinic acetylcholine receptor m2 , muscarinic acetylcholine receptor m3 , muscarinic acetylcholine receptor m1 , methoctramine , atropine , inositol , biology , g protein
Muscarinic receptors (M‐receptors) in the mammalian heart are predominantly of the M 2 ‐subtype. The aim of this study was to find out whether there might exist an additional myocardial non‐M 2 ‐receptor. For this purpose, we assessed, in adult rat isolated ventricular cardiomyocytes, carbachol‐induced [ 3 H]‐inositol phosphate (IP) formation, and its inhibition by M‐receptor antagonists. Carbachol (10 −7 –10 −3 mol l −1 ) increased IP‐formation (maximal increase: 14±3% above basal, n =6). This increase was significantly enhanced by pretreatment with pertussis toxin (PTX, 250 ng ml −1 for 20 h): maximal increase was 31±5%, pEC 50 ‐value was 5.08±0.33 ( n =6). In PTX‐pretreated cardiomyocytes 100 μmol l −1 carbachol‐induced IP‐formation was inhibited by atropine (pK i ‐value: 8.89±0.10) and by the M 3 ‐receptor antagonist darifenacin (pK i ‐value: 8.67±0.23) but was not significantly affected by the M 1 ‐receptor antagonist pirenzepine (1 μmol l −1 ) or the M 2 ‐receptor antagonists AF‐DX 116 and himbacine (1 μmol l −1 ). In conclusion, in adult rat cardiomyocytes there exists an additional, non‐M 2 ‐receptor, that is coupled to activation of the phospholipase C/IP 3 ‐pathway; this receptor is very likely of the M 3 ‐subtype.British Journal of Pharmacology (2003) 138 , 156–160. doi: 10.1038/sj.bjp.0704997

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom